Drugs that contain Tivozanib Hydrochloride

1. List of Fotivda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7166722 AVEO PHARMS N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
Nov, 2023

(5 months from now)

US6821987 AVEO PHARMS Quinoline derivatives and quinazoline derivatives having azolyl group
Apr, 2024

(10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504365 AVEO PHARMS NA
Nov, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 10, 2026

NCE-1 date: 2025-03-10

Market Authorisation Date: 10 March, 2021

Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...

Dosage: CAPSULE;ORAL

More Information on Dosage

FOTIVDA family patents

9

Japan

8

United States

4

European Union

3

Germany

3

Australia

3

Austria

2

Canada

2

Brazil

2

Denmark

2

Spain

2

Norway

1

Chile

1

Poland

1

Korea, Republic of

1

Hong Kong

1

Taiwan

1

China

1

Netherlands

1

Belgium

1

Mexico

1

New Zealand

EA

1

EA

1

South Africa

1

Portugal

1

Russia

1

Israel

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in